A Two-way Communication System to Coach Elderly Patients With Heart Failure
Launched by HASSELT UNIVERSITY · Sep 26, 2017
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 60
- • Patient has to be followed in Ziekenhuis Oost-Limburg or Jessa Ziekenhuis Hasselt and has to live in the region Genk - Hasselt
- • The patient has to be cognitive strong enough and speak enough Dutch to communicate about their health situation and to understand the smartphone application
- • The diagnosis of systolic heart failure or severe myocardial infarction has to be done during consultation or hospitalization
- • Left ventricular ejection fraction (LVEF) \<45%
- • Treatment minimally with ACE-I and BB On the basis of an interview between the heart failure nurse and patient, one will decide if the patient is eligible to join the study. The patient also needs to speak sufficient Dutch to be communicative about his/her medical condition.
- Exclusion Criteria:
- • Reversible form of heart failure
- • Heart failure due to severe aortic stenosis
- • At the time of inclusion a eGFR less than 30ml/min/kg
- • Presence of a cardiac resynchronization therapy (CRT) device
- • Active treatment with either ACE-I/ARB or BB
- • Patient that are subscribed in a cardiac revalidation program when leaving the hospital
- • Patients with severe form of COPD (GOLD III)
About Hasselt University
Hasselt University is a prestigious research institution located in Belgium, renowned for its commitment to advancing scientific knowledge and innovation. With a strong focus on interdisciplinary research, the university actively engages in clinical trials that aim to address pressing health challenges. Leveraging a robust network of collaborations with healthcare professionals, industry partners, and research organizations, Hasselt University strives to translate research findings into practical applications that benefit patient care and public health. The institution is dedicated to maintaining the highest ethical standards and regulatory compliance in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genk, , Belgium
Hasselt, , Belgium
Patients applied
Trial Officials
Vandervoort Pieter, MD, PhD
Study Director
Ziekenhuis Oost-Limburg
Paul Dendale, MD, PhD
Study Director
Jessa Ziekenhuis, Hasselt, Belgium
Jo Ravelingen
Study Director
Remedus, Aartselaar, Belgium
Peter Van Vooren
Study Director
Fifthplay, Antwerpen, Belgium
Valerie Storms, PhD
Study Director
Mobile Health Unit, Hasselt University, Hasselt, Belgium
Lars Grieten, PhD
Principal Investigator
Mobile Health Unit, Hasselt University, Hasselt, Belgium
Christophe Smeets, PhD student
Study Chair
Mobile Health Unit, Hasselt University, Hasselt, Belgium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials